Prostate cancer diagnosis
Transforming complex procedures into confident care
Demonstrated results in prostate cancer diagnosis
+30%
improvement in high-risk prostate cancer diagnosis using fusion
biopsy vs standard biopsy5
-13.3%
reduction in pathological upgrading to clinically significant prostate cancer with targeted and systematic biopsies vs systematic biopsies alone9
+10%
increase in prostate cancers identified with combined targeted and systematic biopsy compared to systematic biopsy alone
Featured products for prostate cancer diagnosis
DynaCAD Prostate
High-quality fusion guided procedures start in radiology, and DynaCAD offers advanced visualization tools for real-time analysis, review and reporting of multi-parametric MR studies
UroNav
UroNav is designed to support you with image guidance during prostate biopsies and focal therapy procedures. It fuses diagnostic MR images of the prostate with live ultrasound images for guided procedures in real time.
Digital pathology
Join the transformation to digital pathology
Our clinical solutions can enhance detection and improve the patient experience by reducing unnecessary biopsies and potentially reducing post-procedure complications. Digital pathology saves time and resources through streamlined collaborative features and case management tools.
“The combination of MRI and ultrasound fusion biopsy is extremely powerful. This technology is too good to ignore.”
Dr. Edward Steiner
Chair of Wellspan Imaging and Radiation Oncology
Wellspan Health, York, PA, USA
Footnotes
[1]Choi YH, et al. Comparison of cancer detection rates between TRUS-guided biopsy and MRI-targeted biopsy according to PSA level in biopsy-naive patients: a propensity score matching analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13. PMID: 30415878.
[2]Yarlagadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men. Diagn Interv Radiol. 2018 May-Jun;24(3):115-120. doi: 10.5152/dir.2018.17422. PMID: 29770762; PMCID: PMC5951198.
[3]Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.71:209-249. https://doi.org/10.3322/caac.21660
[4]Siddiqui MM, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
[5]Sonn GA, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013 Jan;189(1):86-91. doi: 10.1016/j.juro.2012.08.095. Epub 2012 Nov 14. PMID: 23158413; PMCID: PMC3561472.
[6]Loeb S, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062
[7]Rebbeck TR, et al. Temporal trends and racial disparities in global prostate cancer prevalence. Can J Urol. 2014 Oct;21(5):7496-506. PMID: 25347377; PMCID: PMC4955669.
[8]Ahdoot M, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. NEMJ. 2020382:917–928. doi: 10.1056/NEJMoa1910038
[9]Baidoshvili A, et al. Evaluating the benefits of digital pathology implementation: time savings in laboratory logistics. Histopathology. 2018 Nov;73(5):784-794. doi: 10.1111/his.13691. Epub 2018 Aug 13. PMID: 29924891.
Results from case studies are not predictive of results in other cases. Results in other cases may vary.
